BioCryst Pharma (BCRX) Tops Q2 EPS by 4c
Get Alerts BCRX Hot Sheet
Price: $4.50 -1.75%
EPS Growth %: +25.0%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
ESCA, LICT, NKSH, More
EPS Growth %: +25.0%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $3.92 million.
Cash, cash equivalents and investments decreased to $64.3 million at June 30, 2016, as compared to $100.9 million at December 31, 2015. Net operating cash use for the second quarter of 2016 was $15.4 million, as compared to $12.0 million for the second quarter of 2015.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BayCom Corp (BCML) Misses Q1 EPS by 4c
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Endexx Corporation (EDXC) Reports Q1 Loss of $0.01
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!